00000nam 2200000zi 4500 9.919266 CaOODSP 20230313123350 m o d f cr ||||||||||| 230118t20232023onc o f000 0 eng d 9780660471624 CaOODSP eng rda CaOODSP n-cn--- H164-346/2023E-PDF Guidance document : conduct and analysis of comparative bioavailability studies. Ottawa, ON : Health Canada = Santé Canada, 2023. ©2023 1 online resource (35 pages) text txt rdacontent computer c rdamedia online resource cr rdacarrier Issued also in French under title: Ligne directrice : conduite et analyse des études de biodisponibilité comparatives. "Date Adopted: 2012/02/08. Revised Date: 2023/01/30. Effective Date: 2018/09/01 (for submissions filed on or September 1, 2018)." Drugs Testing Government policy Canada. Drugs Bioavailability Canada. Canada. Health Canada, issuing body. Ligne directrice : (CaOODSP)9.919268 Guidance document (CaOODSP)9.852787 PDF 636 KB https://publications.gc.ca/collections/collection_2023/sc-hc/H164-346-2023-eng.pdf 220708